Polymer Melt Polycondensation for Injectable Bioactive Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polylactide often forms solid aggregates, making it difficult to formulate bioactive agents and is not suitable for injectable use without nano- or microparticle formation or additional excipients, limiting its applications.
Innovation Solution
Compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids, including admixtures with releasable agents, are developed to overcome these limitations, allowing for the creation of bioactive agent delivery systems with improved injectability and release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polylactide is used as a polymer for bioactive agent delivery, then it provides biodegradability and biocompatibility, but it forms solid aggregates that make formulation difficult and limits injectable use
Solution Approach 1:
The patent changes the molecular weight parameter of the polylactide polymer, using lower molecular weight polylactide (e.g., 1,000-10,000 Da) compared to conventional high molecular weight polylactide. This parameter change reduces the tendency to form solid aggregates while maintaining biodegradability and biocompatibility, enabling direct formulation with bioactive agents without requiring nano- or microparticle formation
Solution Approach 2:
The patent creates composite formulations by combining lower molecular weight polylactide with bioactive agents in various dosage forms including solutions, suspensions, and emulsions. This composite approach allows the polymer and bioactive agent to be uniformly distributed without aggregate formation, solving the formulation difficulty while maintaining the therapeutic benefits
2Ease of operation
If polylactide is formulated with additional excipients or nano- or microparticle formation, then injectability is achieved, but device complexity and formulation complexity increase
Solution Approach 1:
The patent changes the molecular weight parameter to lower ranges (1,000-10,000 Da) which inherently improves injectability by reducing viscosity and preventing aggregate formation. This eliminates the need for complex nano- or microparticle formation processes and reduces or eliminates the need for additional excipients, thereby reducing formulation complexity while maintaining injectability
3Strength
If conventional polylactide is used, then polymer strength and structural integrity are maintained, but it is not suitable for injectable use without further processing
Solution Approach 1:
The patent optimizes the molecular weight parameter to a specific range (1,000-10,000 Da) that balances structural integrity with injectability. This parameter change ensures the polymer maintains sufficient strength for formulation stability while being soft and flowable enough for direct injection without requiring nano- or microparticle formation or additional excipients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compositions enable the formulation of bioactive agents with polylactide in a form that is injectable and effective, providing controlled release and improved pharmacokinetics, addressing the challenges of solid aggregate formation and suitability for injectable use.
Implementation Method 1
melt polycondensation of 2-hydroxyalkyl acids
Implementation Method 2
poly(hydroxyalkyl acid) polymers
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
Described herein are compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids. Methods of making and using the compositions are also disclosed.